On the other hand, vascular endothelial growth factor (VEGF), a critical mediator of angiogenesis, was observed to be highly expressed in several ovarian surface epithelial neoplasms, inferring that VEGF-targeting monoclonal antibodies may be a kind of potential anti-angiogenic therapy for the treatment of ovarian cancer (Figure 1). Here, VEGFA is linked to ovarian cancer.